Sensorion (ALSEN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and pipeline

• Aims to treat, prevent, and restore hearing loss, including for babies born deaf.

• Pipeline includes two gene therapy programs (SENS-501 and GJB2) and a small molecule (SENS-401).

• SENS-501 targets otoferlin deficiency and is in Phase 1/2; GJB2 addresses the most common genetic cause of congenital deafness.

• SENS-401 is being tested for hearing preservation post-cochlear implantation and for preventing cisplatin-induced ototoxicity.

• Multiple clinical milestones expected in 2025, with strong financial backing and partnerships.

Clinical progress and data

• SENS-501 Phase 1/2: First cohort of toddlers enrolled, showing safety and early behavioral improvements.

• Next cohort to be completed by mid-year; preliminary data to be shared in Q1.

• SENS-401 met primary endpoints in cochlear implant study; full data for cisplatin study due by year-end.

• GJB2 program progressing toward IND/CTA filing by year-end, leveraging learnings from SENS-501.

• Proof-of-concept in animal models shows restoration and maintenance of hearing for both gene therapies.

Differentiation and partnerships

• Clinical design excludes prior cochlear implant recipients and focuses on very young children to maximize speech development outcomes.

• Extensive natural history network enables rapid patient identification and enrollment.

• Exclusive collaboration with Institut Pasteur provides access to leading genetic hearing loss patents.

• Industrial partnerships with Cochlear and Sonova, both shareholders, support clinical and natural history studies.

• Internal CMC capabilities and external GMP manufacturing partnerships ensure robust product development.